Q&A has ended
- All Questions & Answers
- Question: I want to echo the thanks to you both for being part of this session with us....
- Worcester, MA
- St Vincent Hospital, Worcester
I want to echo the thanks to you both for being part of this session with us. As a nephrologist, I was of course interested in the renal aspects of this trial. For instance, in the supplement, it appears that 12.8% in the placebo group and 12.1% in the empagliflozin group developed AKI. Why was the rate of AKI so high in the placebo arm, given that this group of patients with HFpEF likely had reasonable blood pressures? (As a correlate, were small bumps in creatinine after starting the SGLT-2 inhibitor counted for the treatment arm?)
Time Zone: EST